<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6118">
  <stage>Registered</stage>
  <submitdate>18/06/2015</submitdate>
  <approvaldate>18/06/2015</approvaldate>
  <nctid>NCT02484092</nctid>
  <trial_identification>
    <studytitle>A Gene Therapy Study for Hemophilia B</studytitle>
    <scientifictitle>Gene Therapy, Open-label, Dose-escalation Study of SPK-9001 [Adeno-associated Viral Vector With Human Factor IX Gene] in Subjects With Hemophilia B</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>SPK-9001-101</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hemophilia B</healthcondition>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Clotting disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - SPK-9001

Experimental: SPK-9001 - Single intravenous (i.v.) infusion of SPK-9001 [an adeno-associated viral (AAV) vector with human factor IX gene] Intervention: Gene Therapy / Gene Transfer


Other interventions: SPK-9001
A novel, bioengineered adeno-associated viral vector carrying human factor IX variant

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of participants experiencing drug-related adverse events - As assessed by physical exam, vital signs, standard clinical labs, and Bethesda assay for FIX inhibitor</outcome>
      <timepoint>1 year</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Changes from baseline in circulating FIX activity (IU/dL or % normal) - FIX activity</outcome>
      <timepoint>1 Year</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Able to provide informed consent and comply with requirements of the study

          -  Males =18 y.o. with confirmed diagnosis of hemophilia B (=2 IU/dL or =2% endogenous
             factor IX)

          -  Received =50 exposure days to factor IX products

          -  A minimum average of 4 bleeding events per year requiring episodic treatment of factor
             IX infusions or prophylactic factor IX infusions

          -  No measurable factor IX inhibitor as assessed by the central laboratory and have no
             prior history of inhibitors to factor IX protein

          -  Agree to use reliable barrier contraception until 3 consecutive samples are negative
             for vector sequences</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Evidence of active hepatitis B or C

          -  Currently on antiviral therapy for hepatitis B or C

          -  Have significant underlying liver disease

          -  Have serological evidence* of HIV-1 or HIV-2 with CD4 counts =200/mm3 (* subjects who
             are HIV+ and stable with CD4 count &gt;200/mm3 and undetectable viral load are eligible
             to enroll)

          -  Have detectable antibodies reactive with AAV-Spark100

          -  Participated in a gene transfer trial within the last 52 weeks or in a clinical trial
             with an investigational drug within the last 12 weeks

          -  Unable or unwilling to comply with study assessments</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1/Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>15</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/01/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Royal Prince Alfred Hospital - Gene and Stem Cell Therapy Department - Sydney</hospital>
    <postcode>NSW 2050 - Sydney</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Mississippi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Spark Therapeutics</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Pfizer</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A Phase 1/2, Open-Label, Non-Randomized, Dose-Escalation Study of SPK-9001 in Subjects with
      Hemophilia B.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02484092</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Director</name>
      <address>Spark Therapeutics</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Clinical Director</name>
      <address />
      <phone />
      <fax />
      <email>clinicaltrials@sparktx.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>